Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 609

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 609
---
 ​ | ​                              | $ |  15,047 | ​ | ​ | ​ | ​    | $ |  11,884 | ​ | ​ | ​ | ​      | $ |  3,163 | ​ | ​ | ​ | ​       | ​ | 26.6%   | ​ | ​ |
| General and administrative | ​ | ​ | ​                              | ​ |   2,258 | ​ | ​ | ​ | ​    | ​ |   2,117 | ​ | ​ | ​ | ​      | ​ |    141 | ​ | ​ | ​ | ​       | ​ | 6.7%    | ​ | ​ |
| Total operating expenses   | ​ | ​ | ​                              | ​ |  17,305 | ​ | ​ | ​ | ​    | ​ |  14,001 | ​ | ​ | ​ | ​      | ​ |  3,304 | ​ | ​ | ​ | ​       | ​ | 23.6%   | ​ | ​ |
| Loss from operations       | ​ | ​ | ​                              | ​ | -17,305 | ​ | ​ | ​ | ​    | ​ | -14,001 | ​ | ​ | ​ | ​      | ​ | -3,304 | ​ | ​ | ​ | ​       | ​ | 23.6%   | ​ | ​ |
| Interest income            | ​ | ​ | ​                              | ​ |     615 | ​ | ​ | ​ | ​    | ​ |   1,005 | ​ | ​ | ​ | ​      | ​ |   -390 | ​ | ​ | ​ | ​       | ​ | (38.8)% | ​ | ​ |
| Net loss                   | ​ | ​ | ​                              | $ | -16,690 | ​ | ​ | ​ | ​    | $ | -12,996 | ​ | ​ | ​ | ​      | $ | -3,694 | ​ | ​ | ​ | ​       | ​ | 28.4%   | ​ | ​ |

349

TABLE OF CONTENTS

Research and Development Expenses Research and development expenses for the nine months ended September 30, 2024 and 2023 were comprised of the following (in thousands, except percentages):

| ​                                                    
 ​                                                    
 Direct research and development expenses by program: 
 TTI-101:                                             | ​ 
 ​ 
 ​ 
 ​ |